Dr. Reddy’s receives EIR for FTO-3 Bachupally plant
During the inspection, the facility received 10 observations
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Dr Reddy’s Laboratories
Dr Reddy’s acquires MenoLabs, women’s health and dietary supplements portfolio of brands
MenoLabs portfolio of products is sold in the US, primarily through the brand’s own and other e-commerce marketplaces including…
Coya, Dr Reddy’s sign pact to develop and market COYA 302 for treatment of ALS
Coya retains the right to commercialise COYA 302 for patients with amyotrophic lateral sclerosis (ALS) in Japan, Mexico, and each…
Science Magazine names Dr Reddy’s among Top 20 employers in pharma globally
Dr Reddy's is in the list for the second year in a row, placed at number 16 in 2023
Dr Reddy’s launches D2C e-commerce website ‘Celevida Wellness’ for diabetes
Launch enables the company to reach more consumers, strengthens play in nutraceuticals which started in 2019 through its flagship…
Dr Reddy’s Laboratories launch Saxagliptin and Metformin Hydrochloride ER tablets in US
Saxagliptin and metformin hydrochloride ER tablets are indicated as an adjunct to diet and exercise to improve glycemic control in…
Dr Reddy’s selects AWS as cloud provider to develop pharma therapies
With AWS, Dr Reddy’s aims to reduce application development time by 30 per cent
Dr Reddy’s completes Phase I study of DRL_TC, a tocilizumab biosimilar candidate
This Phase I study used an intravenous (IV) formulation to evaluate the pharmacokinetic equivalence, safety and immunogenicity of…
Dr Reddy’s Lab launches Treprostinil Injection in the U.S.
Will be supplied as 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL or 200 mg/20 mL vials
Dr Reddy’s focuses on differentiated portfolio in key therapy areas for growth in India: GlobalData
DRL has earlier this month divested nine dermatology brands to Eris Lifesciences for Rs 2750 million ($33.3 million*). Within a…